ProQR Therapeutics initiated with a Buy at JonesResearch

JonesResearch analyst Catherine Novack initiated coverage of ProQR Therapeutics (PRQR) with a Buy rating and $11 price target The firm says the company brings more than a decade of experience in RNA therapeutics, emerging as a pure-play RNA editing biotech with early-stage programs in both rare disease and more prevalent indications such as liver and cardiovascular disease. The analyst is bullish on the “burgeoning” RNA editing space, believing it to be safer and more versatile than DNA editing, and therefore more broadly applicable.